Allergic Rhino-Conjunctivitis - Market Insight, Epidemiology, and Market Forecast - 2034

Key Highlights

• The total market size of the allergic rhino-conjunctivitis is highest in the US among all the 7MM, which is further expected to increase by 2034.
• Growth of allergic rhino-conjunctivitis market is expected to be driven by increasing cases of allergic rhino-conjunctivitis, mainly due to increase in climate change, exposure to indoor allergens like dust, mold spores, and animal dander, genetics, urbanization, expected entry of potential premium price emerging therapies and readily uptake of currently approved treatment across the 7MM.
• During childhood (0–10 years) prevalence of allergic rhinitis is higher among males compared to females. Quite the reverse, during adolescence (11–17 years) females display higher prevalence of allergic rhinitis compared to males.
• Approximately 50–60% of patients with allergic rhinitis have associated symptoms of allergic conjunctivitis that on total constitutes the cases of allergic rhino-conjunctivitis.
• Symptoms of allergic rhinitis or allergic rhino-conjunctivitis typically develop before the age of 20, with around 40% of individuals experiencing symptoms by the age of 6.
• Allergic rhino-conjunctivitis significantly impacts the physical and mental quality of life (QoL) of adolescents and their parents, with school absences and reduced academic performance resulting from distraction, fatigue, and irritability—further compounded by the sedating effects of first-generation antihistamines.
• The current treatment approaches include intranasal corticosteroids, antihistamines, eye drops, nonsteroidal anti-inflammatory drug (NSAID), mast cell stabilizer, and immunotherapy if needed. The main treatment approach also involves the lifestyle management, avoidance of allergens, and others.
• Individual treatment plans vary based on the severity of symptoms, specific allergens, and the patient's response to therapy. Consulting with a healthcare professional, typically an allergist or immunologist, is essential for personalized and effective management.
• The emerging drug pipeline of allergic rhino-conjunctivitis is not very robust only some drugs are included as MM09, MG01 + T517, and others.
• The current key players in the market related to allergic rhinitis and allergic conjunctivitis are ALK-Abelló, Immunotek and many others.
• Given the substantial burden and productivity loss associated with allergic rhino-conjunctivitis, it holds significant socioeconomic importance; if left untreated, it can lead to comorbidities like atopic dermatitis and potentially progress to more severe conditions such as allergic asthma.
• The unmet market need in allergic rhino-conjunctivitis includes of less patient compliance due to treating allergic rhinitis and conjunctivitis differently and the allergen specific drugs may help to cure the disease more effectively and efficiently. Companies are working in the following to fulfill these unmet demands.

DelveInsight’s “Allergic Rhino-Conjunctivitis – Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of allergic rhino-conjunctivitis, historical and forecasted epidemiology as well as allergic rhino-conjunctivitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The allergic rhino-conjunctivitis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM allergic rhino-conjunctivitis market size from 2020 to 2034. The report also covers current allergic rhino-conjunctivitis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Allergic Rhino-Conjunctivitis Understanding and Treatment Algorithm

Allergic Rhino-Conjunctivitis Overview

Allergic rhino-conjunctivitis is an allergen-induced inflammatory response. Allergic rhino-conjunctivitis is the result of IgE-mediated allergy and nasal mucosa inflammation. IgE is produced in the lymphoid tissues and locally in response to common environmental allergens. When allergens bind to mast-cell-bound IgE, mast-cell degranulation occurs and release of a myriad of biochemical mediators. Histamine is the key player in the acute allergic response. The non-infective, seasonal (SAR) and perennial allergic rhino-conjunctivitis (PAR) are the most common types of allergic rhino-conjunctivitis. Histamine is a well-known mediator responsible for the signs and symptoms of SAR but many other mediators including leukotrienes and prostaglandin D2 are involved. SAR is caused by allergens released by tree, grass or weed pollination (and spores and moulds), whereas PAR results from allergens such as animal dander, dust mites and less frequently from allergens such as cockroaches or mould spores. Symptoms are both nasal and non-nasal. The most prominent nasal symptoms are itching, sneezing, rhinorrhoea and congestion. Non-nasal symptoms commonly associated with allergic rhinitis include tearing, eye itching and redness.

Allergic Rhino-Conjunctivitis Diagnosis

Allergic rhino-conjunctivitis is diagnosed through medical history, symptoms evaluation, physical examination, allergy testing (skin prick, Ig test or blood test), and, if necessary, elimination and challenge tests or nasal endoscopy. The diagnosis of rhino-conjunctivitis is established by the concordance between the symptoms and the diagnostic tests. The concurrent occurrence of nasal and eye symptoms is a key feature of rhinoconjunctivitis. Common symptoms include runny nose, nasal congestion, sneezing, nasal itching, watery eyes, eye swelling, and ocular itching. Patients with allergic conjunctivitis often exhibit distinct facial features, such as a horizontal crease across the bridge of the nose, known as the ""allergic salute,"" caused by frequent nose rubbing.

Further details related to diagnosis are provided in the report…

Allergic Rhino-Conjunctivitis Treatment

There are a number of treatment options for allergic rhino-conjunctivitis. These treatment options are used to treat a specific patient’s that depends on the type of allergen and patient’s overall health. Treatment involves a multifaceted approach to address symptoms and provide long-term management. One crucial aspect is allergen avoidance. Identifying specific allergens, such as pollen, dust mites, pet dander, allows individuals to take measures to minimize exposure. This includes using air purifiers, employing allergen-proof bedding, and maintaining a clean living environment. Allergic rhino-conjunctivitis is treated with allergen avoidance, antihistamines, nasal corticosteroids, eye drops, mast cell stabilizer, and immunotherapy if needed. This combination approach helps alleviate symptoms and provides long-term relief for allergy sufferers. Antihistamines, available over-the-counter or as prescription medications, help alleviate itching, sneezing, and runny nose. Nasal corticosteroid sprays, like fluticasone and mometasone, are effective in reducing nasal congestion and inflammation. Decongestants, both oral and nasal, provide temporary relief from congestion. Immunotherapy is a long-term approach that can be considered for moderate to severe allergies. Subcutaneous Immunotherapy (SCIT), commonly known as allergy shots used in allergic rhino-conjunctivitis.

Further details related to treatment are provided in the report…

Allergic Rhino-Conjunctivitis Epidemiology

As the market is derived using the patient-based model, the allergic rhino-conjunctivitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of allergic rhino-conjunctivitis, diagnosed prevalent cases of allergic rhino-conjunctivitis, age-specific cases of allergic rhino-conjunctivitis, and treatable cases of allergic rhino-conjunctivitis in the 7MM covering the US, EU4 (Germany, France, Italy, Spain) and the UK, and Japan from 2020 to 2034.

• Among the EU4 and the UK, Germany had the highest cases of allergic rhino-conjunctivitis. On the other hand, Spain had the lowest number of cases of allergic rhino-conjunctivitis.
• As per secondary research, in Europe allergic rhino-conjunctivitis was observed in approximately 15% of children aged 13–14 years, indicating a higher prevalence compared to 8.5% in children aged 6–7 years in 2021.
• The lifetime prevalence of allergic rhino-conjunctivitis was found to be 14.8% in Germany.
• According to data from the German Robert Koch Institute, about 15% of the German population suffer from allergic rhino-conjunctivitis.
• As per secondary research, in Japan, the prevalence of allergic rhino-conjunctivitis was 16.2% in younger children and 21.7% in older children.
• Allergic rhino-conjunctivitis, a common chronic inflammatory condition encompassing both allergic rhinitis and allergic conjunctivitis, affects approximately 20% of the global population.
• According to the secondary research, in Japan, the prevalence of allergic rhino-conjunctivitis is 16.2% in younger children (6–7 years) and 21.7% in older children (13–14 years).
• According to our secondary research, it was estimated that the prevalence of rhino-conjunctivitis symptom was 14.6% among 13–14-year-olds (range, 1–45.1%), and for 6–7 year patients the prevalence was 8.5%, along with a wide geographic variations.

Allergic Rhino-Conjunctivitis Drug Chapters

The drug chapter segment of the allergic rhino-conjunctivitis report encloses a detailed analysis of the marketed and the late, mid, and early stage (Phase III, Phase II, and Phase I/II) pipeline drugs. The marketed drugs segment encloses drugs such as GRASTEK, RAGWITEK, ODACTRA, and others. The drug chapter also helps understand the allergic rhino-conjunctivitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.

Marketed Drugs

ODACTRA: ALK-Abello

ODACTRA is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites or by positive skin testing to licensed house dust mite allergen extracts. ODACTRA is an allergy immunotherapy (AIT) tablet which dissolves under the tongue and helps patients reduce their allergy symptoms and their reliance on symptomatic medication. The FDA approval is an important step in ALK’s efforts to make all its respiratory tablets available for all age groups – children, adolescents, and adults - in all relevant markets.

In February 2025, ALK announced that the US Food and Drug Administration (FDA) had approved ALK’s ODACTRA tablet for use in young children with HDM allergy. ODACTRA is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis, in children aged five through 11, in addition to patients aged 12 through 65.

ODACTRA was first approved in the United States in 2017 for adults aged 18–65 for treating house dust mite-induced allergic rhinitis, with or without conjunctivitis. The FDA expanded ODACTRA's approval in 2023 to include adolescents aged 12–17 years.

RAGWITEK: Merck and ALK-Abello

RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. RAGWITEK is approved for use in persons 5 through 65 years of age.

In April 2021, FDA approved ALK's RAGWITEK tablet for sublingual use as immunotherapy for children and adolescents (5–17 years age) with short ragweed pollen-induced allergic rhinitis with or without conjunctivitis.

In April 2014, FDA had given approval to Merck’s RAGWITEK (Short Ragweed Pollen Allergen Extract) sublingual tablet as immunotherapy to treat short ragweed pollen-induced allergic rhinitis with or without conjunctivitis in adults. The approval was based on the efficacy of RAGWITEK was supported by two Phase III clinical studies over a single ragweed pollen season in patients 18 through 50 years of age.

Emerging Drugs

MM09: Immunotek

Immunotek is conducting many trials around MM09. MM09 is a purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) for treatment approach related to mild to moderate asthma and rhinitis/rhino-conjunctivitis. MM09 is an allergoid-mannan conjugates subcutaneous. The company is currently conducting a Phase III clinical trial (NCT05400811), which is not yet recruiting, to evaluate the efficacy and safety of a treatment for HDM-induced allergic asthma and rhinitis/rhinoconjunctivitis.

Also, the company had initiated another Phase III trial (NCT04435990) to determine the efficacy and safety of subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without asthma, sensitised to Dermatophagoides pteronyssinus and /or Dermatophagoides farinae.

Note: Detailed list will be provided in the final report.

Drug Class Insights

Allergen Immunotherapy (AIT)

Allergen immunotherapy is a treatment that can help prevent allergic reactions to substances like grass pollen, house dust mites, and bee venom. It's the only treatment that can modify the course of allergic diseases. AIT can be administered in several ways, including subcutaneous immunotherapy (SCIT), sublingual immunotherapy (SLIT) intranasal, and epicutaneous. AIT is usually recommended for people who are selectively sensitive to several allergens. It's not advised for people with uncontrolled asthma, as there's a higher risk of systemic reactions.

Allergic Rhino-Conjunctivitis Market Outlook

For many patients with allergic rhino-conjunctivitis, allergen immunotherapy (AIT) remains the current standard of care. While numerous studies have demonstrated improved time to symptom control and overall quality of life compared to placebo, emerging therapeutic strategies are now exploring targeted biologics, including monoclonal antibodies that enhance treatment specificity and effectiveness.

Among the limited pipeline activity, Immunotek appears to be the most active company in this space, with ongoing trials listed on ClinicalTrials.gov despite no recent updates on its official website or pipeline disclosures. Additionally, Blueprint Medicines is evaluating BLU-808 in Canada for allergic rhino-conjunctivitis; however, with the company currently prioritizing regulatory approval for BLU-808 in Chronic Spontaneous Urticaria (CSU) in the US, it is likely that an Investigational New Drug (IND) filing for US investigation in allergic rhino-conjunctivitis may follow.

To summarize, the scarce pipeline in allergic rhino-conjunctivitis highlights a significant opportunity for innovation and market entry. As several new therapies gradually emerge, the treatment paradigm is expected to evolve. This presents a strong opportunity for companies to address the substantial unmet medical need, particularly given the high rate of treatment switching and reliance on multi-drug regimens. Physician enthusiasm for novel, more effective therapies is likely to further drive demand, making this a strategically attractive area for pipeline expansion and investment.

The pipeline of allergic rhino-conjunctivitis is not very robust. There are a few key players actively involving in the development of promising products in allergic rhinitis and allergic conjunctivitis such as Immunotek, and others.

Allergic Rhino-Conjunctivitis Drugs Uptake

This section highlights the anticipated uptake of potential drugs projected to enter the market between 2025 and 2034. The current treatment landscape for allergic rhino-conjunctivitis presents a substantial opportunity, as existing regimens largely focus on symptom management rather than disease modification. The current pipeline remains limited, highlighting a clear unmet need for more innovative and disease-modifying treatment options. This gap presents a strong opportunity for pharmaceutical investment, as patients and physicians continue to seek alternatives beyond conventional symptom-relief therapies. The increasing adoption of these innovative treatments reflects the commitment of physicians, researchers, and the broader healthcare community to improve patient outcomes. This evolving treatment paradigm underscores the impact of scientific advancement, cross-sector collaboration, and the collective effort to address a long-standing unmet need in allergic rhino-conjunctivitis.

Further detailed analysis of emerging therapies drug uptake in the report…

Allergic Rhino-Conjunctivitis Pipeline Development Activities

The report provides insights into therapeutic candidates in Phase III, Phase II, and Phase I/II. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for allergic rhino-conjunctivitis emerging therapy.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on allergic rhino-conjunctivitis 's evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including physician, and others.

Delveinsight’s analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 05+ KOLs in the 7MM. Centers such as -Tottori University in Japan, University of Toyama in Japan, University of Tennessee Health Science Center in the US, University Hospital Dresden in Germany, and were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or allergic rhino-conjunctivitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyses multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyse the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated.

Further, the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and this clearly explains the drug's side effects in the trials. In addition, the scoring is also based on the probability of success and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Globally, allergic rhino-conjunctivitis patient families spend an essential proportion of their household income on allergic rhino-conjunctivitis care. Allergic rhino-conjunctivitis patients have to face a huge economic burden alone without any healthcare coverage or proper reimbursement policies.

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Further detailed analysis of emerging therapies drug uptake in the report…

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of allergic rhino-conjunctivitis, explaining its causes, signs, symptoms, pathogenesis, and currently used therapies.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and treatment guidelines has been provided.
• Additionally, an all-inclusive account of the emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the allergic rhino-conjunctivitis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM allergic rhino-conjunctivitis market.

Report Insights

• Patient Population
• Therapeutic Approaches
• Allergic Rhino-Conjunctivitis Pipeline Analysis
• Allergic Rhino-Conjunctivitis Market Size and Trends
• Existing and Future Market Opportunity

Allergic Rhino-Conjunctivitis Report Key Strengths

• Ten Years Forecast
• The 7MM Coverage
• Allergic Rhino-Conjunctivitis Epidemiology Segmentation
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

Allergic Rhino-Conjunctivitis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT Analysis and Conjoint Analysis)

FAQs

• What was the allergic rhino-conjunctivitis market size, the market size by therapies, market share (%) distribution in 2024, and what would it look like by 2034? What are the contributing factors for this growth?
• What are the pricing variations among different geographies for approved therapies?
• What can be the future treatment paradigm of allergic rhino-conjunctivitis?
• What are the disease risks, burdens, and unmet needs of allergic rhino-conjunctivitis? What will be the growth opportunities across the 7MM concerning the patient population with allergic rhino-conjunctivitis?
• What are the current options for the treatment of allergic rhino-conjunctivitis? What are the current guidelines for treating allergic rhino-conjunctivitis in the US, Europe, and Japan?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitations of existing therapies?

Reasons to Buy

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the allergic rhino-conjunctivitis market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the Analyst view section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of current therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Please Note: It will take 7-10 business days to complete the report upon order confirmation. Show more